Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Murphy

Allergy & Immunology Charleston, SC Medical Doctor

NPI 1144275827 CMS profile 97323

2295 Henry Tecklenburg Dr, Charleston, SC 29414

Open in the dashboard

General payments

$652,950

1,049 records reported · program years 2019–2025

Research payments

$9,468

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$30,272

1 holding reported · through program year 2025

Research they led as principal investigator

$790,176 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Thomas Murphy of Charleston, SC is reported in the CMS Open Payments database as having received $652,950 across 1,049 general payments and $9,468 in research payments paid to them. Separately, studies naming them as principal investigator received $790,176 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $30,272 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $116,517 206
2024 General $110,628 163
2023 General $87,165 152
2023 Research $1,746 6
2022 General $70,462 136
2022 Research $2,157 2
2021 General $54,217 97
2021 Research $5,566 3
2020 General $43,054 47
2019 General $170,908 248
2021 Ownership $30,272 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Murphy
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Thomas Murphy were reported at $116,517. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Thomas Murphy Allergy & Immunology median Middle half National median
2019 $170,908 $594 $163–$1,512 $163
2020 $43,054 $426 $106–$1,233 $114
2021 $54,217 $638 $157–$1,708 $132
2022 $70,462 $790 $205–$1,961 $149
2023 $87,165 $852 $220–$2,147 $160
2024 $110,628 $865 $203–$2,267 $164
2025 $116,517 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $309,073 463 payments
  2. Genzyme Corporation $88,097 106 payments
  3. OptiNose US, Inc. $68,755 99 payments
  4. Regeneron Healthcare Solutions, Inc. $53,957 93 payments
  5. GlaxoSmithKline, LLC. $52,216 69 payments
  6. Genentech USA, Inc. $43,618 63 payments
  7. F. Hoffmann-La Roche AG $12,329 13 payments
  8. Amgen Inc. $8,040 11 payments
  9. Novartis Pharmaceuticals Corporation $6,259 15 payments
  10. ALK-Abello, Inc $3,785 16 payments
  11. Other $6,820 101 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $542,894 271 payments
  2. Travel and Lodging $45,612 214 payments
  3. Consulting Fee $40,228 28 payments
  4. Food and Beverage $21,616 521 payments
  5. Honoraria $2,150 2 payments
  6. Education $452 13 payments
Products named General payments · program years 2019–2025
  1. TEZSPIRE $105,234 136 payments
  2. FASENRA Respiratory $91,977 129 payments
  3. DUPIXENT Immunology $86,334 114 payments
  4. Xhance $68,755 99 payments
  5. AIRSUPRA $57,054 88 payments
  6. Xolair $53,281 77 payments
  7. DUPIXENT Inflammation And Immunology $44,592 77 payments
  8. FASENRA Respiratory $39,837 88 payments
  9. NUCALA Immunology $35,748 51 payments
  10. NUCALA Respiratory $16,439 14 payments
  11. Other $33,136 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $7,723 5 payments
  2. Insmed, Inc. $1,746 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,340

Median for Allergy/ Immunology: 449

Drug cost

$383,426

Median for Allergy/ Immunology: $169,700

Branded share of claims

18.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 37 $165,423
Dupixent Syringe Dupilumab Brand 11 $74,071
Xolair Omalizumab Brand 14 $48,474
Spiriva Respimat Tiotropium Bromide Brand 30 $23,661
Azelastine Hcl Generic 519 $14,262
Epinephrine Generic 51 $8,962
Xhance Fluticasone Propionate Brand 12 $8,794
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $8,233
Symbicort Budesonide/Formoterol Fumarate Brand 22 $6,761
Fluticasone Propionate Generic 325 $5,125

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$81,761

Medicare's payments for the services billed

Medicare patients

430

Average age 72

Services billed

2,935

289 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 54%
Diabetes 27%
Depression 22%
Osteoporosis 20%
Ischemic heart disease 18%
Chronic kidney disease 18%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$56,623 48 —
AIRSUPRA
$21,095 — —
TEZSPIRE
$14,923 — —
FASENRA
$9,451 — —
Xhance
$6,074 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

1,060 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record